Press releases
- Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
More ▼
Key statistics
On Friday, Organon & Co (7XP:FRA) closed at 20.36, -6.61% below its 52-week high of 21.80, set on Aug 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.19 |
---|---|
High | 20.36 |
Low | 20.09 |
Bid | 20.40 |
Offer | 20.51 |
Previous close | 20.23 |
Average volume | 2.19k |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.44 |
Market cap | 5.71bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 1.04 EUR |
---|---|
Annual div yield (ADY) | 5.11% |
Div ex-date | May 10 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 15 minutes, as of Jul 26 2024 20:55 BST.
More ▼